+91-33-4600-9199  (India), +1-414-240-5010 (U.S.)

CAR T CELL THERAPY MARKET (BY TARGETED ANTIGEN – HER1, HER2, CD19, CD20, CD22, CD30, CD33, GD2, MESO AND EGFRVIII, BY TREATMENT - NON-HODGKIN LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), MULTIPLE MYELOMA, ACUTE MYELOID LEUKEMIA (AML), BREAST CANCER, PANCREATIC CANCER, NEUROBLASTOMA (NB), COLON CANCER AND HEPATOCELLULAR CARCINOMA (HCC)) – GLOBAL INDUSTRY ANALYSIS, SIZE, SHARE, GROWTH, TRENDS AND FORECAST, 2017 – 2025

Published Date : December, 2017 | Report Id : HC120-2 | Format : Word PDF, PPT PDF, Excel | Slides : 155
Report Type : Syndicate Report

In the cancer therapeutics field, a unique kind of cancer immunotherapy known as the ‘CAR T cell therapy’ has brought a transformation in the healthcare sector by Carl June. This type of individualized form of cancer intervention procedure has shown the potential for curing the blood cancer along with other cancer types and to some extent even solid tumors.

 

The immunotherapy or the CART T cell therapy mainly works with the immunity system of the patient unlike other chemotherapies and conventional radiotherapies. It helps in the eradication of the germ cells which causes cancer from its source. In this case, the T cells, a type of white blood cells, gets removed from the blood of the patient, followed by the addition of a receptor that is known as CAR T cell or “Chimeric Antigen Receptor” T Cell. These T cells are then engineered into millions of T cells for re-introducing them inside the patient’s body. These CAR T cells that are genetically harvested kill the myeloma cells. In case of the B-cell acute lymphoblastic leukemia (B-ALL), the CD19 CAR T cells have shown extraordinary remission properties.

 

The chimeric antigen receptor or the CAR T cell is a type of antibody that is induced with the modular fusion protein along with having an extracellular binding domain. Because of this quality, the CAR T cell therapy is now an indispensable source for treating and guarding against the recurrence of blood cancer or any other carcinogenic cases.

 

In the cancer therapeutics field, the CAR T cell therapy is considered to be a boon and has been adopted by many healthcare centers because of which the market is expected to augment in the upcoming years. Kite Pharma Inc., Novartis International AG, and Juno Therapeutics are some of the major industry players in the global CAR T cell therapy market. Currently, the CD 19 antigen is considered to be the most successful targeted antigen known for treating acute lymphoblastic leukemia (ALL). Clinical trials are being conducted to curb the risk of acute myeloid leukemia and solid tumors by using CAR T cell therapy.

 

Growing cases of cancer and other technological advancements are helping in the growth of the global CAR T cell therapy market. This is also creating growth opportunities for the existing and the new industry players. However, the long process of the clinical trials along with higher rates of therapy packages is hampering the growth of the market.

 

The global CAR T cell therapy market has been characterized on the basis of treatment, targeted antigen, and by geographical demand. The targeted segment of the global CAR T cell therapy market includesHER1, HER2, CD19, CD20, CD22, CD30, CD33, GD2, MESO, and EGFRvIII. The Treatment type section of the market includes chronic lymphocytic leukemia (CLL), a non-Hodgkin lymphoma (NHL), multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), pancreatic cancer, breast cancer, colon cancer, neuroblastoma (NB), and hepatocellular carcinoma (HCC). In this case, the acute lymphoblastic leukemia group is controlling the other disease segment.

 

Geographically, the global CAR T cell therapy market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa. Amongst all these regions, the North American region holds the largest market share in the global CAR T cell therapy market owing to the increasing number of blood cancer patients along with the rising scientific researches in the same field. Kite PharmaInc. and Novartis AG has already applied for the FDA and BLA (Biologics License Application) for the US region. The Asia Pacific region is projected to witness the highest CAGR in terms of its growth during the forecast period 2017-2025.

 

The report also includes the detailed company profiles of the key industry players of the global CAR T cell therapy market. the prominent industry players include companies like Kite Pharma Inc., Novartis International AG, Juno Therapeutics, Bellicum Pharmaceuticals Inc. Cellectis, and Celgene Corporation among others.

 

The global CAR T cell therapy market has been segmented into:

Global CAR T Cell Therapy Market: By Targeted Antigen

  • HER1
  • HER2
  • CD19
  • CD20
  • CD22
  • CD30
  • CD33
  • GD2
  • MESO and
  • EGFRvIII

Global CAR T Cell Therapy Market: By Treatment

  • Non-Hodgkin lymphoma (NHL)
  • Chronic lymphocytic leukemia (CLL)
  • Acute lymphoblastic leukemia (ALL)
  • Multiple myelomas
  • Acute myeloid leukemia (AML)
  • Breast cancer
  • Pancreatic cancer
  • Neuroblastoma (NB)
  • Colon cancer and
  • Hepatocellular carcinoma (HCC)

Global CAR T Cell Therapy Market: By Geography

North America

  • The U.S.
  • Canada
  • Mexico

Europe

  • U.K.
  • Italy
  • France
  • Germany
  • Russia
  • Spain
  • Rest of Europe

Asia Pacific

  • India
  • China
  • Japan
  • Australia
  • Rest of Asia Pacific

The Middle East and Africa

  • GCC
  • South Africa
  • Rest of the Middle East and Africa

Latin America

  • Brazil
  • Rest of Latin America

Questions answered in the CAR T cell therapy market report:

  1. What is CAR T Cell Therapy?
  2. What is Cancer Immunotherapy?
  3. What is the global CAR T market size?
  4. What is global cancer immunotherapy market size?
  5. Which factors are driving the global CAR T cell therapy market?
  6. What is the market trends and forecast of CAR T cell therapy market?
  7. What does market research and analysis based on the segmentation of CAR T market by targeted antigen say about global trends and forecasts?
  8. What does market research and analysis based on the segmentation of CAR T market by treatment say about global trends and forecasts?
  9. What does market research and analysis based on the segmentation of CAR T market by geography say about global trends and forecasts?
  10. Which are the major CAR T therapy companies operating globally?
Note: This table of contents is a content of a published report. As per client requirement, cross-sectional analysis across all industries or specific geography or ‘country-based’ analysis can be provided as a part of paid customization. Please place your queries on sales@sheeranalyticsandinsights.com or query@sheeranalyticsandinsights.com

Buy Chapters or Sections

Customization options available to meet your custom research requirements :

  • Request a part of this report
  • Get geography specific report
  • Request historical analysis
  • Check out special discounted pricing

Why Choose Us

  • Research support24/5 Research support

    Get queries resolved by industry expert.

  • Custom research serviceCustom research service

    Exclusive reports and studies to meet your custom requirements.

  • Quality assuranceQuality assurance

    Widely acclaimed services reccomended by major organizations.

  • Information securityInformation security

    Your personal information security guaranteed.

  • sheer analytics and insights PCI DSS complaintsheer analytics and insights paypal verified
Registered Office
RDB Boulevard, 8th Floor, Plot K 1, Sector 5, Block EP and GP, Kolkata 700091, India.
Contact Us
+91-33-4600-9199
+1-414-240-5010
sales@sheeranalyticsandinsights.com
Stay Informed
Submit Your Query
Hot Links